| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
TT-OAD2 HCl (TT-OAD-2 dihyrochloride; TT-OAD 2) is a novel and potent non-peptidyl agonist of glucagon-like peptide-1 (GLP-1) receptor agonist with potential anti-diabetic effects. It activates GLP-1 an EC50 of 5 nM.
| Targets |
GLP-1 receptor (EC50 = 5 nM)[2]
|
|---|---|
| ln Vitro |
In HEK293A cells, TT-OAD2 (0-10 μM) concentration-dependently suppresses GLP-1 and oxyntomodulin-mediated cAMP, calcium, pERK1/2, and β-arrestin responses [1].
|
| ln Vivo |
Male human GLP-1 receptor knock-in and knock-out mice treated with TT-OAD2 (3 mg/kg; i.v.) had acute IVGTT in humanized GLP-1R knock-in (KI) and GLP-1R knock-out (KO) mice, and this treatment is successful [1].
|
| Enzyme Assay |
NanoBRET ligand binding[1]
HEK293A cells were transiently transfected with Nluc-hGLP-1R. Forty-eight hours after transfection, cells were collected and plasma membrane was extracted as described previously31. Cell membrane (1 μg per well) was incubated with furimazine (1:1,000 dilution from stock) in assay buffer (1× HBSS, 10 mM HEPES, 0.1% (w/v) BSA, 1× P8340 protease inhibitor cocktail, 1 mM DTT and 0.1 mM PMSF, pH 7.4). RhodamineX-Ex4 (Rox-Ex4) was used as fluorescent ligand in the NanoBRET binding assay. BRET signal between Nluc-hGLP-1R and Rox-Ex4 was measured using PHERAstar at 10 s interval (25 °C), a 2 min baseline was taken before addition of Rox-Ex4 (Kd concentration 3.16nM, determined previously), the measurement continued for 15 min followed by adding increasing concentration of TT-OAD2, or unlabelled Ex4 as a control. Data were corrected for baseline and vehicle treated samples. cAMP kinetics studies[1] HEK293A cells (confirmed mycoplasma negative) were transfected with an Epac-cAMP sensor and human GLP-1R at an optimized ratio. Ligand-mediated cAMP production was measured 48 h after transfection. In brief, culture media was replaced with assay buffer (1× HBSS, 10 mM HEPES, 0.1% BSA, pH 7.4). BRET signals were measured at 1 min intervals using a PHERAstar plate reader (BMG LabTech) in the absent or present of increasing concentration of ligands. Forskolin (100 μM) was used as a positive control, and data were normalized to the forskolin response. ERK1/2 phosphorylation assays[1] HEK293 cells (confirmed mycoplasma negative) expressing stably expressing the GLP-1R were seeded at a density of 30,000 cells per well into 96-well culture plates and incubated overnight at 37 °C in 5% CO2. Receptor-mediated pERK1/2 was determined using the AlphaScreen ERK1/2 SureFire protocol as previously described14. Data were normalized to the maximal response elicited by 10% FBS determined at 6 min. In one series of experiments, vehicle or increasing concentrations of TT-OAD2 was added 30 min before assay of peptide response. |
| Cell Assay |
Ca2+ mobilization assays[1]
HEK293 cells (confirmed mycoplasma negative) stably expressing the GLP-1R were seeded at a density of 30,000 cells per well into 96-well culture plates and incubated overnight at 37 °C in 5% CO2, and receptor- mediated intracellular calcium mobilisation determined as previously described65. Fluorescence was determined immediately after ligand addition, with an excitation wavelength set to 485 nm and an emission wavelength set to 520 nm, and readings taken every 1.36 s for 120 s. The peak value was used to create concentration-response curves. Data were normalized to the maximal response elicited by 100 μM ATP. In one series of experiments, vehicle or increasing concentrations of TT-OAD2 was added 30 min before assay of peptide response. β-arrestin recruitment assays[1] HEK293 cells (confirmed mycoplasma negative) were transiently transfected with GLP-1R-Rluc8 and β-arrestin1-Venus at a 1:4 ratio and seeded at a density of 30,000 cells per well into 96-well culture plates and incubated for 48 h in DMEM containing 5% FBS at 37 °C in 5% CO2. β-arrestin recruitment was performed as previously described66. In one series of experiments, vehicle or increasing concentrations of TT-OAD2 was added 30 min before assay of peptide response. cAMP accumulation assays[1] HEK293 cells (confirmed mycoplasma negative) were seeded at a density of 30,000 cells per well into 96-well culture plates and incubated overnight in DMEM containing 5% FBS at 37 °C in 5% CO2. cAMP detection was performed as previously described in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthin65. All values were converted to cAMP concentration using a cAMP standard curve performed in parallel and data were subsequently normalized to the response of 100 μM forskolin in each cell line. In one series of experiments, vehicle or increasing concentrations of TT-OAD2 was added 30 min before assay of peptide response. |
| Animal Protocol |
Animal/Disease Models: Male human GLP-1 receptor knock-in and knock-out mice (6-11 months old), intravenous (iv) (iv)glucose tolerance test [1]
Doses: 3 mg/kg Route of Administration: intravenous (iv) (iv)injection (single dose) Experimental Results: Induction of plasma insulin. In vivo IVGTT assays[1] Intravenous glucose tolerance tests were performed in male human GLP-1R knock-in and knockout mice (all on C57/BL6 background). Catheters were placed in the right carotid artery and left jugular vein of mice 6–11 months of age. Approximately one week later, mice (n = 4–5 per group) were fasted overnight and the catheters were exteriorized as mice acclimated to test cages. Vehicle (5% DMSO, 20% Captisol in NaHPO4, pH 2, 1 ml kg−1), GLP-1(7-36)NH2 at 10 μg kg−1, GIP(1-42) at 25 μg kg−1, or OAD2 at 3 mg kg−1 was administered intravenously one minute before glucose load (0.5 g kg−1). Blood samples were collected at −10, 0, 2, 4, 6, 10, 20 and 30 min to determine blood glucose concentrations via glucometer and plasma insulin measurement.[1] |
| References |
[1]. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.
[2]. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1. |
| Additional Infomation |
Class B G protein-coupled receptors are major targets for the treatment of chronic diseases including diabetes and obesity.1 The structure of the active receptor shows that peptide agonists bind deep to the receptor core, causing the top of extracellular loop 3 and transmembrane helices 6 and 7 to move outward, transmembrane helice 1 to move inward, extracellular loop 2 to recombine, and the intracellular side of transmembrane helice 6 to move outward, ultimately leading to G protein interaction and activation2-6. This paper resolves the structure of the binding of the non-peptide agonist TT-OAD2 to the glucagon-like peptide-1 (GLP-1) receptor. Our structure reveals an unexpected non-peptide agonist binding pocket in which the recombination of extracellular loop 3 and transmembrane helices 6 and 7 occurs independently of the direct interaction between the ligand and the deep transmembrane domain pocket. TT-OAD2 exhibits biased agonistic activity, and its G protein activation and signal transduction kinetics are distinctly different from those of peptide agonists. In its structure, TT-OAD2 protrudes beyond the receptor core and interacts with lipids or detergents, which explains its unique activation kinetics, which may contribute to the clinical efficacy of this series of compounds. This work changes our understanding of events driving the activation of class B receptors. [1]
|
| Molecular Formula |
C50H49CL4N3O6
|
|---|---|
| Molecular Weight |
929.752569913864
|
| Exact Mass |
927.237
|
| Elemental Analysis |
C, 67.23; H, 5.42; Cl, 11.91; N, 4.70; O, 10.75
|
| CAS # |
2382719-60-8
|
| Related CAS # |
TT-OAD2 free base;1246826-07-2
|
| PubChem CID |
146026066
|
| Appearance |
Typically exists as Off-white to yellow solid at room temperature
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
63
|
| Complexity |
1400
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC[C@@H](C1=CC=CC=C1)N2CC3=CC4=C(C=C3C[C@H]2C(=O)N[C@@H](CC5=CC=C(C=C5)C6=C(C(=NC=C6)C)C)C(=O)O)OC[C@@H](O4)C7=CC=C(C=C7)OCC8=CC(=C(C=C8)Cl)Cl.Cl.Cl
|
| InChi Key |
JCHUZLPPFLKGNX-PLFFULENSA-N
|
| InChi Code |
InChI=1S/C50H47Cl2N3O6.2ClH/c1-4-44(35-8-6-5-7-9-35)55-27-38-26-47-46(60-29-48(61-47)36-15-17-39(18-16-36)59-28-33-12-19-41(51)42(52)22-33)25-37(38)24-45(55)49(56)54-43(50(57)58)23-32-10-13-34(14-11-32)40-20-21-53-31(3)30(40)2;;/h5-22,25-26,43-45,48H,4,23-24,27-29H2,1-3H3,(H,54,56)(H,57,58);2*1H/t43-,44-,45-,48+;;/m0../s1
|
| Chemical Name |
(2S)-2-[[(3S,8S)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-7-[(1S)-1-phenylpropyl]-3,6,8,9-tetrahydro-2H-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]amino]-3-[4-(2,3-dimethylpyridin-4-yl)phenyl]propanoic acid;dihydrochloride
|
| Synonyms |
TTOAD2; TT OAD2; TT-OAD2
2382719-60-8
(S)-2-((3S,8S)-3-(4-((3,4-Dichlorobenzyl)oxy)phenyl)-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carboxamido)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propanoic acid dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0756 mL | 5.3778 mL | 10.7556 mL | |
| 5 mM | 0.2151 mL | 1.0756 mL | 2.1511 mL | |
| 10 mM | 0.1076 mL | 0.5378 mL | 1.0756 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
